...
首页> 外文期刊>American journal of rhinology & allergy >A retrospective comparison of acute rhinosinusitis outcomes in patients prescribed antibiotics, mometasone furoate nasal spray, or both
【24h】

A retrospective comparison of acute rhinosinusitis outcomes in patients prescribed antibiotics, mometasone furoate nasal spray, or both

机译:处方抗生素,糠酸莫米他松鼻喷剂或两者并用的患者急性鼻-鼻窦炎预后的回顾性比较

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Antibiotics are frequently used to treat acute rhinosinusitis (ARS; acute sinusitis), although many episodes are viral. Because of community resistance concerns, current evidence provides limited support for the use of antibiotics in ARS. We conducted a retrospective comparative effectiveness outcomes assessment of the nasal steroid mometasone furoate nasal spray (MFNS) versus antibiotics among ARS patients in clinical practice. Methods: Using the General Practice Research Database (United Kingdom), the earliest ARS event between January 1, 2005 and December 31, 2008 (index event) for patients aged 12-75 years and an antibiotic or MFNS prescription ±2 days was identified. Treatment cohorts were MFNS monotherapy (MM), MFNS + antibiotic (MAT), and antibiotic monotherapy (AM). Logistic regression adjusted for potential confounders and compared odds of rhinosinusitis-related medical encounters and related prescriptions in the 3- to 30-day postindex period. Results: There were 12,679 eligible patients (651 MM; 2285 MAT; 9743 AM). Compared with the reference cohort AM, during the 3- to 30-day postindex period, lower adjusted odds (p < 0.001) of having one or more rhinosinusitis-related medical encounters was observed for MM (odds ratio [OR] = 0.39; 95% CI, 0.26-0.58) and MAT (OR = 0.51; 95% CI, 0.42-0.62); having one or more rhinosinusitis-related prescriptions for MM (OR = 0.51; 95% CI, 0.42-0.63) and MAT (OR = 0.58; 95% CI, 0.52-0.65); having one or more antibiotic, nasal steroid, or oral steroid prescriptions for MM (OR = 0.36; 95% CI, 0.28-0.46) and MAT (OR = 0.51; 95% CI, 0.46-0.58); and having one or more antibiotic prescriptions for MM (OR = 0.43; 95% CI, 0.33-0.58) and MAT (OR = 0.63; 95% CI, (0.55-0.72). Conclusion: Compared with AM, using MFNS for initial ARS treatment, alone or with an antibiotic, is associated with a decreased likelihood of both subsequent rhinosinusitis-related medical encounters and use of related prescriptions.
机译:背景:尽管许多发作都是病毒性的,但抗生素通常用于治疗急性鼻鼻窦炎(ARS;急性鼻窦炎)。由于社区的抵制问题,目前的证据为ARS中使用抗生素提供了有限的支持。在临床实践中,我们对ARS患者中的鼻类固醇糠酸莫米松鼻喷剂(MFNS)与抗生素进行了回顾性比较有效性结果评估。方法:使用英国通用实践研究数据库,确定了2005年1月1日至2008年12月31日之间最早的ARS事件(索引事件),年龄在12-75岁之间,使用抗生素或MFNS处方±2天。治疗人群为MFNS单一疗法(MM),MFNS +抗生素(MAT)和抗生素单一疗法(AM)。 Logistic回归针对潜在的混杂因素进行了调整,并比较了在索引后3至30天与鼻-鼻窦炎相关的医疗经历和相关处方的几率。结果:有12679名合格患者(651 MM; 2285 MAT; 9743 AM)。与参考队列AM相比,在索引后的3至30天期间,MM发生一次或多次与鼻-鼻窦炎相关的医疗经历的调整后机率(p <0.001)较低(赔率[OR] = 0.39; 95) %CI,0.26-0.58)和MAT(OR = 0.51; 95%CI,0.42-0.62);具有MM(OR = 0.51; 95%CI,0.42-0.63)和MAT(OR = 0.58; 95%CI,0.52-0.65)的一种或多种与鼻-鼻窦炎相关的处方;具有MM(OR = 0.36; 95%CI,0.28-0.46)和MAT(OR = 0.51; 95%CI,0.46-0.58)的一种或多种抗生素,鼻类固醇或口服类固醇处方;并具有一种或多种针对MM(OR = 0.43; 95%CI,0.33-0.58)和MAT(OR = 0.63; 95%CI,(0.55-0.72)的抗生素处方。结论:与AM相比,使用MFNS进行初始ARS单独或与抗生素一起进行治疗,与随后发生的与鼻-鼻窦炎相关的医疗遭遇以及使用相关处方的可能性均降低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号